XTL Biopharma files to raise $40m on Nasdaq
"Korea JoonAng Daily" reports that Teva held initial talks with Handok Pharmaceuticals.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) is interested in acquiring a Korean pharmaceutical company, and Handok Pharmaceuticals Co. Ltd. (KSX: 2390) is a possible target, according to the "Korea JoonAng Daily" in a report on the local pharmaceutical industry.
Handok Pharmaceuticals has a market cap of 184 billion won ($170 million). Assuming that Teva wants to acquire the company, and even if it pays a substantial premium for it, the acquisition willd not be a big deal, given Teva's $2 billion in cash reserves.
Handok said, "We are continuing preliminary talks with an Israeli company."
Teva president and CEO Jeremy Levin has said several times that the company would make no big acquisitions in the near future. Teva said in response today, "We have nothing to add to what was stated by Handok. If we have something to report, we'll report it."
Handok, founded in 1954, is run by chairman and CEO Young-Jin Kim, who is also the controlling shareholder. It develops and sells brand and over-the-counter drugs. The company jointly develops with other companies in the research and development of oncology, cardiovascular, and central nervous system disease treatments. Kim owns 46.8% of the company and Korean firm IMM Private Equity owns 30%. In September, Kim and IMM bought out Sanofi-Aventis SA's (NYSE: SNY; Euronext: SAN) stake in Handok.
10% of South Korea's population of 49 million is over the age of 65. Although the elderly consume more medications, local drug companies are coping with a government decision from a few months ago to cut drug prices, which is hitting the companies' profits. Teva is apparently undeterred by this.
Published by Globes [online], Israel business news - www.globes-online.com - on November 15, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012
You comment was recieved and soon will be published.
Load more comments
XTL plans to initiate a large Phase IIb clinical trial for the treatment of Lupus.
Teva launches generic cancer drug
Brand Xeloda, made by Genentech, had $754 million in US sales in 2013.
Yelin Lapidot takes stake in Brainsway
Brainsway raised NIS 41 million in the private placement.
Barclays upgrades Teva
Barclays raised its recommendation to "Overweight" and its target price to $65.
BiolineRX raises $24m in Nasdaq offering
Three months ago, the company announced promising preliminary clinical trial results.
Teva VP Ika Abravanel resigns
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.
Israeli biomed cos bring in US CEOs
"Globes" speaks to 3 US CEOs appointed to boost marketing at TASE traded medical device companies.
Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.
Restructuring can help Teva's Copaxone woes
Avishai Ovadia argues that Teva can offset falling Copaxone sales by reducing overall company costs.
Enabling diabetes patients to sleep soundly
Excess insulin levels can be fatal when they occur at night. NightSense aims to remove the fear.